non-small cell lung cancer

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways

Research in Review

Veliparib Effectiveness for NSCLC Linked to Smoking-Related Genetic Signature

12/06/2016

JCP Editors

Tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations in their tumors that may underlie their increased responsiveness to veliparib, according to new research. ----- Related...

...

12/06/2016

Journal of Clinical Pathways

Research in Review

Incorporating EGFR, ALK Gene Alterations Data Improves Survival Prediction for Patients With NSCLC

11/21/2016

JCP Editors

Patients with non-small cell lung cancer (NSCLC) may see improved survival predictions as a result of a new prognostic tool that includes EGFR and ALK gene alterations data, according to an analysis published...

...

11/21/2016

Journal of Clinical Pathways

Research in Review

Testing for PD-L1 Expression to Determine Lung Cancer Treatment

11/17/2016

JCP Editors

Using PD-L1 expression to determine non-small cell lung cancer (NSCLC) treatment is becoming standard of care, according to a presentation given at the 11th Annual New York Lung Cancer Symposium (November 12,...

Using...

11/17/2016

Journal of Clinical Pathways

Research in Review

Pembrolizumab More Cost Effective Than Docetaxel for PD-L1-Positive NSCLC

10/31/2016

JCP Editors

The associated improvement in survival and quality-adjusted life years (QALYs) makes pembrolizumab a more cost-effective option than docetaxel for patients with programmed death ligand 1 (PD-L1)-positive non-small...

The...

10/31/2016

Journal of Clinical Pathways

Department

Hypofractionated Radiation Therapy Safer, Halves Treatment Time in NSCLC

09/27/2016

JCP Editors

Hypofractionated radiation therapy is less toxic and just as effective as conventional radiation therapy in patients with non-small cell lung cancer (NSCLC), according to research presented at the 58th Annual Meeting...

...

09/27/2016

Journal of Clinical Pathways

Research in Review

ALK Inhibitor Treatment Response Better Predicted With Combo Genetic Screening

09/26/2016

JCP Editors

Combining fluorescence in situ hybridization (FISH) analysis and immunohistochemistry (IHC) assays may help to identify rare anaplastic lymphoma kinase (ALK) mutations in patients with non-small cell lung...

...

09/26/2016

Journal of Clinical Pathways

Research in Review

Evidence for Liquid Biopsy Use in Lung Cancer Grows

09/14/2016

JCP Editors

A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...

A...

09/14/2016

Journal of Clinical Pathways

Research in Review

Treatment Combination Improves NSCLC Survival and Response

08/12/2016

JCP Editors

East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...

East...

08/12/2016

Journal of Clinical Pathways

Research in Review

Better Biomarker-Driven Treatment Strategies Needed for NSCLC

08/11/2016

JCP Editors

A trial assessing the clinical effectiveness of biomarker-based treatments provided additional support for the use of targeted therapeutic options, but also called attention to the need for better biomarker-driven...

A...

08/11/2016

Journal of Clinical Pathways